In a new study published in Nature Communications, researchers from the University of Colorado Anschutz Medical Campus have discovered preliminary evidence suggesting that the use of antidepressants during pregnancy can have significant effects on brain development, specifically impacting the development of connections within the brain’s prefrontal cortex. This region of the brain is crucial for complex cognitive functions such as decision-making, personality expression, and social behavior.
The study, conducted on rodents, sheds light on the role that serotonin, a key neurotransmitter affected by antidepressants, plays in brain maturation during early development.
Understanding SSRIs and the Motivation Behind the Study
Selective serotonin reuptake inhibitors (SSRIs) are a class of drugs commonly prescribed to treat depression, including during pregnancy. They work by increasing the levels of serotonin in the brain, a chemical thought to have a good influence on mood, emotion, and sleep. Given the prevalence of their use, understanding the implications of SSRIs on pregnancy and fetal development is of paramount importance.
Previous research has hinted at potential risks, yet definitive evidence on how these drugs affect the developing brain at a cellular level has been scarce. Motivated by this gap in knowledge, the researchers aimed to explore the direct impact of SSRIs on the brain’s prefrontal cortex during critical periods of development.
“Given the high levels of the serotonin in early brain development in animals including humans, coinciding with the period of intense brain maturation, we hypothesized that serotonergic activity is important for proper development of the prefrontal cortex that receives dense serotonergic innervation throughout development,” explained study author Won Chan Oh, an assistant professor of pharmacology at the University of Colorado School of Medicine.
“The prefrontal cortex, the most evolved brain region, plays a central role in highest-order cognition, which is why we focused our study on finding the answer from this brain area.”
Investigating the Effects of SSRIs on Brain Development
To examine the effects of altered serotonin signaling in mice, which share critical periods of brain development with humans, the researchers employed both chemogenetic and pharmacological manipulations.
Chemogenetics involves the use of engineered receptors, known as Designer Receptors Exclusively Activated by Designer Drugs (DREADDs), which can be selectively activated or inhibited by specific, otherwise pharmacologically inert, small molecules. In this study, DREADDs were used to selectively control the activity of serotonin-producing neurons in a precise manner.
This method relies on genetic engineering to express these synthetic receptors specifically in target neuron populations—in this case, serotoninergic neurons. By employing DREADDs, researchers could mimic the effects of increased or decreased serotonin levels without the need for pharmacological SSRIs.
For the pharmacological manipulation, the researchers orally administered fluoxetine (commonly known by brand names such as Prozac and Sarafem) to mouse pups shortly after birth. The timing was chosen to coincide with a significant phase of brain development in rodents.
Serotonin’s Impact on Dendritic Spine Density
One of the study’s core findings was the bidirectional modulation of dendritic spine development by serotonin signaling. Dendritic spines are small, protruding structures on neurons that form synaptic connections, facilitating communication between neurons. The density and maturity of these spines are critical for brain function, impacting everything from learning and memory to decision-making.
In chemogenetic experiments where serotonin signaling was diminished, researchers observed a significant reduction in spine density on layer 2/3 pyramidal neurons in the prefrontal cortex. This suggests fewer synaptic connections, potentially leading to impaired cognitive functions.
Conversely, when serotonin signaling was enhanced—mimicking the effect of fluoxetine administration—there was an increase in spine density and synaptic strength, indicating more robust neural connections.
SSRIs and Postnatal Prefrontal Cortex Development
The researchers also found that fluoxetine exposure leads to an increase in spine density and synaptic strength in the prefrontal cortex, effects that were dependent on the activation of 5-HT2A and 5-HT7 receptors. This suggests that elevated serotonin levels, as a result of SSRI use, can lead to changes in the architecture and function of neural circuits.
“Our research uncovers the specific mechanisms at the synaptic level that explain how serotonin may contribute to the development of the prefrontal cortex during early-life fluoxetine exposure,” Oh told PsyPost. “Our experimental evidence shows the direct impact of serotonin on the developing prefrontal cortex in mice.”
The timing of fluoxetine exposure during postnatal development was found to be crucial; administering the drug during the first two weeks of life led to significant effects. However, when fluoxetine treatment was delayed until the third week of postnatal development, these changes in synaptic density and strength were not observed.
The study suggests that SSRI use during pregnancy could alter offspring brain development. But the consequences of this — whether positive or negative — are unclear.
“We provided experimental evidence of the direct impact of enhanced serotonin signals on the developing prefrontal cortex in mice,” Oh explained. “Fluoxetine not only crosses the placenta but also passes into breast milk, leading to increased serotonin in the fetus. However, pregnant women who are currently taking antidepressants SHOULD NOT stop taking it. They should discuss with their providers the benefits and side effects of antidepressants and possible non-pharmacological interventions for postpartum depression.”
Limitations and Future Directions
While this study represents a significant leap in understanding the effects of SSRIs on fetal brain development, it also underscores the complexity of brain development and the need for caution in interpreting these results. The research was conducted on mice, and while these models provide invaluable insights into human biology, differences between species mean that further research is necessary to fully understand the implications for human development.
“Although we discovered that serotonin has a specific role in influencing how individual connections between neurons change and adapt, contributing to the brain’s ability to learn and adjust, we CANNOT generalize our findings from mice to human brain development,” Oh emphasized.
The study opens up several avenues for future research. Investigating the long-term behavioral and cognitive outcomes of altered serotonin signaling during development is crucial. Additionally, exploring the impact of SSRIs on the brain during other critical developmental windows, such as adolescence, will provide a more comprehensive understanding of these drugs’ effects.
“We want to study the long-term effects of deficiency and surplus of serotonin on mouse behaviors, specifically behaviors observed in mouse ASD (autism spectrum disorder) models,” Oh said.
The study, “Serotonin modulates excitatory synapse maturation in the developing prefrontal cortex,” was authored by Roberto Ogelman, Luis E. Gomez Wulschner, Victoria M. Hoelscher, In-Wook Hwang, Victoria N. Chang, and Won Chan Oh.
